Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study

Introduction Mortality and disability in diabetes mellitus are determined mostly by cardiovascular complications and cancer. The impact of dipeptidyl peptidase-4 inhibitor (DPP-4i) and sodium-glucose cotransporter-2 inhibitor (SGLT2i) monotherapy or combination on long-term complications of type 2 d...

Full description

Bibliographic Details
Published in:	BMJ Open Diabetes Research & Care
Main Authors:	Gyula Poór, Gábor Sütő, Gergő A Molnár, Gyorgy Rokszin, Ibolya Fábián, Zoltan Kiss, György Jermendy, Peter Kempler, István Wittmann
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2021-10-01
Online Access:	https://drc.bmj.com/content/9/1/e001765.full

Similar Items

Dissimilar impact of type 2 diabetes on cardiovascular outcomes according to age categories: a nationwide population study from Hungary
by: Zoltán Kiss, et al.
Published: (2018-07-01)

Changing Patterns of Antihyperglycaemic Treatment among Patients with Type 2 Diabetes in Hungary between 2015 and 2020—Nationwide Data from a Register-Based Analysis
by: György Jermendy, et al.
Published: (2022-10-01)

Sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic macular edema and the need for intravitreal injection
by: Yoo-Ri Chung, et al.
Published: (2025-07-01)

Comparison of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Steatotic Liver Disease
by: Yunmi Ko, et al.
Published: (2025-09-01)

Dipeptidyl peptidase-1 inhibitors in bronchiectasis
by: Emma Johnson, et al.
Published: (2025-06-01)

SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS
by: M. Ganeva
Published: (2023-03-01)

Angioedema associated with dipeptidyl peptidase-IV inhibitors
by: Nicoletta Cassano, et al.
Published: (2021-12-01)

Cardioprotective effects of sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase 4 inhibitor in type 2 diabetes: A meta-analysis of comparative safety and efficacy
by: Abhigan Babu Shrestha, et al.
Published: (2024-07-01)

Identification of phytoconstituents from Houttuynia cordata Thunb. as dipeptidyl peptidase-IV and sodium glucose cotransporter 2 inhibitors guided by molecular docking
by: Careen Liza Pakyntein, et al.
Published: (2024-08-01)

Dipeptidyl peptidase-4 inhibitors: their role in the management of type 2 diabetes
by: Gail Mkele
Published: (2013-12-01)

Sodium‐glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new‐onset overall cancer in Type 2 diabetes mellitus: A population‐based study
by: Cheuk To Chung, et al.
Published: (2023-06-01)

Urate-lowering effects of dipeptidyl peptidase-4 inhibitors
by: Taras S. Panevin, et al.
Published: (2020-12-01)

Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment
by: Ruili Yin, et al.
Published: (2022-05-01)

Dipeptidyl peptidase 4 inhibitors in modern domestic practice
by: A. S. Ametov, et al.
Published: (2020-05-01)

Health economic evaluation of dipeptidyl peptidase-4 inhibitors
by: Vishvas Garg
Published: (2011-01-01)

Atherothrombotic Outcomes After Sodium‐Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase‐4 Inhibitors in Patients With Type 2 Diabetes: A Territory‐Wide Retrospective Cohort Study
by: Pauline Yeung Ng, et al.
Published: (2025-01-01)

Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes
by: Bernd Richter, et al.
Published: (2008-08-01)

Combination Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor and a Dipeptidyl Peptidase-4 Inhibitor Additively Suppresses Macrophage Foam Cell Formation and Atherosclerosis in Diabetic Mice
by: Michishige Terasaki, et al.
Published: (2017-01-01)

Inhibitors of dipeptidyl-peptidase-4: obvious and probable (literature review)
by: E. A. Ortenberg, et al.
Published: (2022-06-01)

Adverse cardiovascular, limb, and renal outcomes in patients with diabetes after peripheral artery disease revascularization treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors
by: Hsin-Fu Lee, et al.
Published: (2023-01-01)

Dipeptidyl peptidase-4 inhibitors alleviate cognitive dysfunction in type 2 diabetes mellitus
by: Jie Meng, et al.
Published: (2023-12-01)

Vipidia is a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
by: T. B. Morgunova, et al.
Published: (2015-12-01)

Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study
by: Han Eol Jeong, et al.
Published: (2023-02-01)

Changes in glucose-induced plasma active glucagon-like peptide-1 levels by co-administration of sodium–glucose cotransporter inhibitors with dipeptidyl peptidase-4 inhibitors in rodents
by: Takahiro Oguma, et al.
Published: (2016-12-01)

UNEXPECTED ADVERSE REACTIONS OF THE DRUGS OF THE GROUP OF INHIBITORS OF DIPEPTIDYL PEPTIDASE-4
by: T. V. Romanova, et al.
Published: (2018-06-01)

Hyperglycaemia induced osteoporosis: Is there a hope with dipeptidyl peptidase-4 inhibitors?
by: Faraha Ahmed, et al.
Published: (2023-12-01)

A review on cardiovascular outcome studies of dipeptidyl peptidase-4 inhibitors
by: Maneesha Khalse, et al.
Published: (2018-01-01)

The association between sodium glucose cotransporter‐2 inhibitors vs dipeptidyl peptidase‐4 inhibitors and renal outcomes in people discharged from hospital with type 2 diabetes: A population‐based cohort study
by: Kate E. D. Ziser, et al.
Published: (2024-04-01)

Effectiveness of SARS-CoV-2 primary vaccines and boosters in patients with type 2 diabetes mellitus in Hungary (HUN-VE 4 Study)
by: Miklos Kasler, et al.
Published: (2024-02-01)

The role of dipeptidyl peptidase 4 inhibitors in fat metabolism in patients with type 2 diabetes and obesity
by: Aleksander Sergeevich Ametov, et al.
Published: (2015-10-01)

The Effects of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Disease Risks in Type 2 Diabetes Mellitus
by: Pegah Yousefzadeh, et al.
Published: (2013-01-01)

Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
by: Cristina Mega, et al.
Published: (2017-01-01)

Pharmacogenetics of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus: A review
by: Iuliia G. Samoilova, et al.
Published: (2024-01-01)

Dipeptidyl peptidase IV inhibitors and the risk of mycobacterial pulmonary infections in type 2 diabetes mellitus
by: Cheng-Yi Wang, et al.
Published: (2023-11-01)

Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus
by: Lin YH, et al.
Published: (2019-12-01)

Association between dipeptidyl peptidase-4 inhibitors use and leptin in type 2 diabetes mellitus
by: Xin Wei, et al.
Published: (2021-08-01)

Effects of dipeptidyl peptidase‐4 inhibition in vivo: Dipeptidyl peptidase‐4 inhibitor/gut microbiome crosstalk suggests novel therapeutic options for diabetes management
by: Takuma Yasuda, et al.
Published: (2024-06-01)

The Potential of some Plant Extracts as Radical Scavengers and Dipeptidyl Peptidase-4 Inhibitors
by: Malik et al.
Published: (2019-03-01)

C-Peptide Levels Predict the Effectiveness of Dipeptidyl Peptidase-4 Inhibitor Therapy
by: Sevin Demir, et al.
Published: (2016-01-01)

Pemphigoid nodularis induced by long-term use of dipeptidyl peptidase-4 inhibitors
by: Natsumi Norikawa, et al.
Published: (2023-01-01)